Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Creative Commons License

Blackhall F., Jao K., Greillier L., Cho B. C. , Penkov K., Reguart N., ...More

JOURNAL OF THORACIC ONCOLOGY, vol.16, no.9, pp.1547-1558, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 9
  • Publication Date: 2021
  • Doi Number: 10.1016/j.jtho.2021.02.009
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.1547-1558
  • Keywords: Small cell lung cancer, Rovalpituzumab tesirine, Delta-like protein 3, Topotecan, CELL LUNG-CANCER, DRUG
  • Hacettepe University Affiliated: Yes


Introduction: DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate containing a DLL3-targeting antibody tethered to a cytotoxic agent pyrrolobenzodiazepine by means of a protease-cleavable linker. The efficacy and safety of Rova-T compared with topotecan as second-line therapy in patients with SCLC expressing high levels of DLL3 (DLL3-high) was evaluated.